cannabis indica

Diabetes

O acervo do Cannabis Indica reúne 218 estudos científicos que tocam a condição Diabetes, publicados entre 1893 e 2024. Pela leitura automatizada, 175 (80%) foram classificados como favoráveis, 18 (8%) como inconclusivos e 25 (11%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (85 estudos), seguido de estudo em animais (59). Os compostos mais presentes são Endocanabinoide (não especificado), Anandamida (AEA) e 2-Araquidonoilglicerol (2-AG). Aparece com frequência ao lado de Síndrome Metabólica, Obesidade e Doenças Cardiovasculares (DCV).

Estudos indexados
218
Período coberto
1893–2024
Favoráveis
175 · 80%
Inconclusivos
18 · 8%
Desfavoráveis
25 · 11%
Termo original
Diabetes

O acervo em números

Tipo de estudo

Metanálise85
Estudo em Animais59
Ensaio Clínico32
Ensaio Clínico Duplo-Cego19
Estudo Laboratorial18
Metanálise Clínica5

Direção do resultado

Favorável175
Inconclusivo18
Desfavorável25

Por década

1890s1
2000s19
2010s104
2020s94

218 estudos

Filtrar e buscar no acervo →
  1. 2024

    Cold-induced changes in plasma signaling lipids are associated with a healthier cardiometabolic profile independently of brown adipose tissue

  2. 2024

    In vivo effects of Cannabis sativa L. extract on blood coagulation, fat and glucose metabolism in normal and streptozocin-induced diabetic rats

    FavorávelEstudo em AnimaisSíndrome MetabólicaDistúrbios de Coagulação
  3. 2023

    A Case of a Patient With Cannabis Hyperemesis Syndrome Along With Recurrent Nephrolithiasis

    DesfavorávelMetanáliseDorInflamaçãoEfeitos Adversos da Cannabis+7
  4. 2023

    A daily diary investigation of cannabis use and its diet and exercise correlates

  5. 2023

    A Phase I Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety Profile of a Sublingually Administered Cannabidiol /Delta 9-tetrahydrocannabidiol (10: 1) Regimen in Diabetes Type 2 Patients

    FavorávelEnsaio Clínico Duplo-CegoSíndrome Metabólica
  6. 2023

    A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis

    FavorávelEnsaio Clínico Duplo-CegoGastroparesiaHidrolase de Amidas de Ácidos Graxos (FAAH)CBD Farmacêutico
  7. 2023

    Cannabidiol-Loaded Extracellular Vesicles from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Paclitaxel-Induced Peripheral Neuropathy

    FavorávelEstudo LaboratorialCâncerInflamaçãoEstresse OxidativoTHC Farmacêutico+12
  8. 2023

    Cannabinoid Hyperemesis Syndrome in a 23-Year-Old Woman with Uncontrolled Type 1 Diabetes Mellitus

  9. 2023

    Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review

  10. 2023

    Late Onset Diaphragmatic Hernia: A Forgotten Etiology of Recurrent Vomiting in the Adolescent Population

    DesfavorávelMetanáliseDorNáusea e VômitoSíndrome da Hiperêmese Canabinoide
  11. 2023

    Resolvin E1 heals injured cardiomyocytes: Therapeutic implications and H-FABP as a readout for cardiovascular disease & systemic inflammation

  12. 2023

    Screening of Spirulina Components for Anti-Parkinson's and Anti-Alzheimer's Activity by in Silico Methods and Docking Studies

    FavorávelEstudo LaboratorialCâncerEstresse OxidativoDoenças NeurodegenerativasFicocianina+2
  13. 2022

    (Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders

  14. 2022

    A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoAnsiedadeAnandamida (AEA)Palmitoiletanolamida (PEA)+5
  15. 2022

    Activation of the endocannabinoid system mediates cardiac hypertrophy induced by rosiglitazone

  16. 2022

    Cannabidiol in Treatment of Autism Spectrum Disorder: A Case Study

  17. 2022

    Cannabidiol-Treated Ovariectomized Mice Show Improved Glucose, Energy, and Bone Metabolism With a Bloom in Lactobacillus

    FavorávelEstudo em AnimaisInflamaçãoSíndrome MetabólicaOsteoporose+2
  18. 2022

    Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort

  19. 2022

    Circulating endocannabinoid levels in pregnant women with gestational diabetes mellitus: a case-control study

    DesfavorávelMetanáliseGestaçãoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)
  20. 2022

    Curcumin Protects Diabetic Mice against Isoproterenol-Induced Myocardial Infarction by Modulating CB2 Cannabinoid Receptors

    FavorávelEstudo em AnimaisCúrcuma
  21. 2022

    Differentiating Diabetic Ketoacidosis and Hyperglycemic Ketosis Due to Cannabis Hyperemesis Syndrome in Adults With Type 1 Diabetes

  22. 2022

    Distinct Effects of Cannabidiol on Sphingolipid Metabolism in Subcutaneous and Visceral Adipose Tissues Derived from High-Fat-Diet-Fed Male Wistar Rats

    FavorávelEstudo em AnimaisSíndrome Metabólica
  23. 2022

    E-cigarette vaping associated acute lung injury (EVALI): state of science and future research needs

    DesfavorávelMetanáliseCâncerAnsiedadeDoenças Cardiovasculares (DCV)+16
  24. 2022

    Effects of Cannabidiol on Appetite and Body Weight: A Systematic Review

    FavorávelMetanáliseAnsiedadeEpilepsiaObesidadeTetraidrocanabinol (THC)+5
  25. 2022

    Exploring the endocannabinoidome in genetically obese (ob/ob) and diabetic (db/db) mice: Links with inflammation and gut microbiota

  26. 2022

    Fetal Exposure to Cannabis and Childhood Metabolic Outcomes: The Healthy Start Study

    DesfavorávelEnsaio ClínicoSíndrome MetabólicaGestaçãoCanabigerol (CBG)Canabinol (CBN)+2
  27. 2022

    Geraniol ameliorates the progression of high fat-diet/streptozotocin-induced type 2 diabetes mellitus in rats via regulation of caspase-3, Bcl-2, and Bax expression

    FavorávelEstudo em Animais
  28. 2022

    Hypoglycemic, Hypolipidemic, and Anti-Inflammatory Effects of Beta-Pinene in Diabetic Rats

    FavorávelEstudo em AnimaisInflamaçãoSíndrome Metabólica
  29. 2022

    Improved glycemic status, insulin resistance and inflammation after receiving oral oleoylethanolamide supplement in people with prediabetes: a randomized controlled trial

    FavorávelEnsaio Clínico Duplo-CegoInflamaçãoSíndrome MetabólicaOleoiletanolamida (OEA)
  30. 2022

    In vitro, In vivo and In silico Antihyperglycemic Activity of Some Semi-Synthetic Phytol Derivatives

    FavorávelEstudo em Animais
  31. 2022

    Malignant Syphilis in a Female Patient: A Case Report and Mini-Review

    DesfavorávelMetanáliseCâncerInflamaçãoEfeitos Adversos da Cannabis+11
  32. 2022

    Opposite physiological and pathological mTORC1-mediated roles of the CB1 receptor in regulating renal tubular function

    InconclusivoEstudo em AnimaisDoença Renal Crônica
  33. 2022

    Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: A meta-analysis

  34. 2022

    Sex differences in endocannabinoids during 3 years of Mediterranean diet intervention: Association with insulin resistance and weight loss in a population with metabolic syndrome

  35. 2022

    Sex Differences in the Association Between Cannabis Use and Diabetes Mellitus among U.S. Adults: The National Health and Nutritional Examination Survey, 2013-2018

    FavorávelMetanálise
  36. 2022

    Spinal cannabinoid CB1 or CB2 receptors activation attenuates mechanical allodynia in streptozotocin-induced diabetic rats

  37. 2022

    Syndrome of Inappropriate Antidiuretic Hormone Secretion Following Ayahuasca Use in a Satanic Ritual: A Case Report

    DesfavorávelMetanáliseDoenças Cardiovasculares (DCV)EpilepsiaPsicoseAyahuasca+6
  38. 2022

    The Characteristics of Clinical Trials on Cannabis and Cannabinoids: A Review of Trials for Therapeutic or Drug Development Purposes

    FavorávelMetanálise ClínicaDorCâncerAnsiedade+5
  39. 2022

    The Endocannabinoid System and Physical Activity—A Robust Duo in the Novel Therapeutic Approach against Metabolic Disorders

  40. 2022

    Three of a Kind: Control of the Expression of Liver-Expressed Antimicrobial Peptide 2 (LEAP2) by the Endocannabinoidome and the Gut Microbiome

  41. 2022

    Vitamin D mitigates diabetes-associated metabolic and cognitive dysfunction by modulating gut microbiota and colonic cannabinoid receptor 1

    FavorávelEstudo em AnimaisDisfunção CognitivaObesidadeSíndrome MetabólicaMicrobioma+1
  42. 2021

    (+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB 1 R antagonist/CB 2 R agonist that prevents diabetic nephropathy in mice

    FavorávelEstudo em AnimaisDorSíndrome MetabólicaInsuficiência Renal+2
  43. 2021

    A cannabinoid type 2 (CB2) receptor agonist augments NOS-dependent responses of cerebral arterioles during type 1 diabetes

    FavorávelEstudo em AnimaisCanabinoides Sintéticos JWH-x
  44. 2021

    A molecular explanation of cardiovascular protection through abnormal cannabidiol: Involving the dysfunctional β-adrenergic and ATP-sensitive K+ channel activity in cardiovascular compromised preterm infants

  45. 2021

    A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Adults With Diabetic Nephropathy

  46. 2021

    Acute effects of hemp protein consumption on glycemic and satiety control: results of two randomized crossover trials

    FavorávelEnsaio ClínicoObesidadeSíndrome Metabólica
  47. 2021

    Anti-Inflammatory and Pro-Autophagy Effects of the Cannabinoid Receptor CB2R: Possibility of Modulation in Type 1 Diabetes

  48. 2021

    Antidiabetic Potential of Naturally Occurring Sesquiterpenes: A Review

    FavorávelMetanálise
  49. 2021

    Associations of Serum Fatty Acid Proportions with Obesity, Insulin Resistance, Blood Pressure, and Fatty Liver: The Cardiovascular Risk in Young Finns Study

  50. 2021

    Caloric restriction, physical exercise, and CB1 receptor blockade as an efficient combined strategy for bodyweight control and cardiometabolic status improvement in male rats

  51. 2021

    Cannabidiol - A phytocannabinoid that widely affects sphingolipid metabolism under conditions of brain insulin resistance

    FavorávelEstudo em AnimaisDoenças NeurodegenerativasObesidadeDoença de Alzheimer+1
  52. 2021

    Cannabigerol and cannabichromene in Cannabis sativa L.

  53. 2021

    Cannabis sativa subsp. sativa's pharmacological properties and health effects: A scoping review of current evidence

    FavorávelMetanáliseInflamaçãoDoenças Cardiovasculares (DCV)Artrite+5
  54. 2021

    Change in Refractive Error Associated With the Use of Cannabidiol Oil

  55. 2021

    D-limonene: A multifunctional compound with potent therapeutic effects

    FavorávelMetanáliseCâncerInflamaçãoDoenças Cardiovasculares (DCV)+1
  56. 2021

    Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial

  57. 2021

    Effect of β-Caryophyllene on insulin resistance in skeletal muscle of high fat diet and fructose-induced type-2 diabetic rats

    FavorávelEstudo em AnimaisSíndrome Metabólica
  58. 2021

    Evaluation of cannabidiol's inhibitory effect on alpha-glucosidase and its stability in simulated gastric and intestinal fluids

    FavorávelEstudo Laboratorial
  59. 2021

    GPR119 and GPR55 as Receptors for Fatty Acid Ethanolamides, Oleoylethanolamide and Palmitoylethanolamide

    FavorávelMetanáliseDorInflamaçãoDor — CrônicaPalmitoiletanolamida (PEA)+2
  60. 2021

    Juvenile cannabidiol chronic treatments produce robust changes in metabolic markers in adult male Wistar rats

    InconclusivoEstudo em AnimaisDoenças Cardiovasculares (DCV)Síndrome MetabólicaAVC
  61. 2021

    Linking the Endocannabinoidome with Specific Metabolic Parameters in an Overweight and Insulin-Resistant Population: From Multivariate Exploratory Analysis to Univariate Analysis and Construction of Predictive Models

  62. 2021

    Mediterranean diet consumption affects the endocannabinoid system in overweight and obese subjects: possible links with gut microbiome, insulin resistance and inflammation

  63. 2021

    Metabolic Consequences of Gestational Cannabinoid Exposure

  64. 2021

    Myrcene—What Are the Potential Health Benefits of This Flavouring and Aroma Agent?

    FavorávelMetanáliseDorCâncerInflamaçãoEndocanabinoide (não especificado)+9
  65. 2021

    Plant-Derived Trans-β-Caryophyllene Boosts Glucose Metabolism and ATP Synthesis in Skeletal Muscle Cells through Cannabinoid Type 2 Receptor Stimulation

    FavorávelEstudo LaboratorialSíndrome Metabólica
  66. 2021

    Protein Kinases Mediate Anti-Inflammatory Effects of Cannabidiol and Estradiol Against High Glucose in Cardiac Sodium Channels

    FavorávelEstudo LaboratorialInflamaçãoDoenças Cardiovasculares (DCV)Estresse Oxidativo+1
  67. 2021

    Real-Time Imaging of Immune Modulation by Cannabinoids Using Intravital Fluorescence Microscopy

    FavorávelMetanáliseInflamaçãoArtriteArtrite — Osteoartrite+2
  68. 2021

    The effects of cannabis and cannabinoids on the endocrine system

    InconclusivoMetanáliseEfeitos Adversos da CannabisSíndrome MetabólicaGestação+1
  69. 2021

    The Effects of Intermittent Hypoxic-Hyperoxic Exposures on Lipid Profile and Inflammation in Patients With Metabolic Syndrome

  70. 2021

    The gut microbiome, endocannabinoids and metabolic disorders

  71. 2021

    Therapeutic Attributes of Endocannabinoid System against Neuro-Inflammatory Autoimmune Disorders

    FavorávelMetanáliseCâncerInflamaçãoEsclerose Múltipla+2
  72. 2021

    Therapeutic Prospects of Cannabinoids in the Immunomodulation of Prevalent Autoimmune Diseases

    FavorávelMetanáliseEsclerose MúltiplaArtriteArtrite — Reumatoide+1
  73. 2020

    A Secondary Analysis from a Randomized Trial on the Effect of Plasma Tetrahydrocannabinol Levels on Pain Reduction in Painful Diabetic Peripheral Neuropathy

    FavorávelMetanálise ClínicaDorDor — CrônicaDor — Neuropatia DiabéticaTetraidrocanabinol (THC)
  74. 2020

    Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort)

    FavorávelMetanáliseFibroseHepatiteFibrose — Hepática (Cirrose)
  75. 2020

    Cannabis Use Is Associated With Increased Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes: Findings From the T1D Exchange Clinic Registry

    DesfavorávelMetanálise
  76. 2020

    Chronic Cannabidiol Administration Attenuates Skeletal Muscle De Novo Ceramide Synthesis Pathway and Related Metabolic Effects in a Rat Model of High-Fat Diet-Induced Obesity

    FavorávelEstudo em AnimaisObesidadeSíndrome Metabólica
  77. 2020

    CRISPR/Cas9 gene editing demonstrates metabolic importance of GPR55 in the modulation of GIP release and pancreatic beta cell function

    FavorávelEstudo em AnimaisCanabinoides Sintéticos AM-xCanabinoides Sintéticos O-x+1
  78. 2020

    Debunking Cannabidiol as a Treatment for COVID-19: Time for the FDA to Adopt a Focused Deterrence Model?

    DesfavorávelMetanáliseCâncerDepressãoDoença de Alzheimer+1
  79. 2020

    Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential?

  80. 2020

    GPR119 Is a Potent Regulator of Human Sebocyte Biology

  81. 2020

    High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain

    FavorávelEstudo em AnimaisObesidadeCanabinoides Sintéticos SR-xTetraidrocanabivarina (THCV)
  82. 2020

    Impact of a weight loss and fitness intervention on exercise-associated plasma oxylipin patterns in obese, insulin-resistant, sedentary women

  83. 2020

    Marijuana use and acute myocardial infarction: A systematic review of published cases in the literature

  84. 2020

    Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes

  85. 2020

    Palmitoylethanolamide counteracts hepatic metabolic inflexibility modulating mitochondrial function and efficiency in diet-induced obese mice

  86. 2020

    Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets

  87. 2020

    Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol

    FavorávelMetanáliseObesidadeSíndrome Metabólica
  88. 2020

    Plant-derived natural therapeutics targeting cannabinoid receptors in metabolic syndrome and its complications: A review

    FavorávelMetanáliseEstresse OxidativoSíndrome MetabólicaFibrose+1
  89. 2020

    Role of the endocannabinoid system in the regulation of the skeletal muscle response to exercise

  90. 2020

    The effects of chronic Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) use on cerebral glucose metabolism in multiple sclerosis: a pilot study

    InconclusivoMetanáliseEsclerose MúltiplaSíndrome Metabólica
  91. 2020

    The effects of recreational cannabis use on glycemic outcomes and self-management behaviours in people with type 1 and type 2 diabetes: a rapid review

    DesfavorávelMetanáliseSíndrome Metabólica
  92. 2020

    Therapeutic Potential of β-Caryophyllene: A Dietary Cannabinoid in Diabetes and Associated Complications

    FavorávelMetanálise
  93. 2020

    Whey protein supplementation reducing fasting levels of anandamide and 2-AG without weight loss in pre-menopausal women with obesity on a weight-loss diet

  94. 2020

    Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes

    FavorávelMetanáliseObesidadeEsteatose HepáticaTetraidrocanabivarina (THCV)
  95. 2019

    A Novel Standardized Cannabis sativa L. Extract and Its Constituent Cannabidiol Inhibit Human Polymorphonuclear Leukocyte Functions

    FavorávelEstudo LaboratorialDorInflamaçãoDoenças Cardiovasculares (DCV)+7
  96. 2019

    A systematic review of cannabidiol dosing in clinical populations

    FavorávelMetanálise ClínicaDorDependência — CannabisAnsiedade+14
  97. 2019

    Blood-brain barrier disturbances in diabetes-associated dementia: Therapeutic potential for cannabinoids.

    FavorávelMetanáliseDisfunção Cognitiva
  98. 2019

    Cannabidiol improves metabolic dysfunction in middle-aged diabetic rats submitted to a chronic cerebral hypoperfusion

    FavorávelEstudo em AnimaisDoenças Cardiovasculares (DCV)
  99. 2019

    Cannabidiol induces antidepressant and anxiolytic-like effects in experimental type-1 diabetic animals by multiple sites of action

    FavorávelEstudo em AnimaisAnsiedadeDepressão
  100. 2019

    Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?

  101. 2019

    Cannabis: From a Plant That Modulates Feeding Behaviors toward Developing Selective Inhibitors of the Peripheral Endocannabinoid System for the Treatment of Obesity and Metabolic Syndrome

  102. 2019

    Countering the Modern Metabolic Disease Rampage With Ancestral Endocannabinoid System Alignment

  103. 2019

    Diabetes Canada Position Statement on Recreational Cannabis Use in Adults and Adolescents With Type 1 and Type 2 Diabetes

    InconclusivoMetanálise
  104. 2019

    Effects of Cannabidiol on Diabetes Outcomes and Chronic Cerebral Hypoperfusion Comorbidities in Middle-Aged Rats

    FavorávelEstudo em AnimaisDisfunção Cognitiva
  105. 2019

    Effects of Cannabis Use in Youth and Young Adults With Type 1 Diabetes: The Highs, the Lows, the Don't Knows

    InconclusivoMetanáliseEfeitos Adversos da Cannabis
  106. 2019

    Lifetime marijuana use in relation to insulin resistance in lean, overweight, and obese US adults

    FavorávelMetanáliseObesidadeSíndrome Metabólica
  107. 2019

    Medical Cannabinoids for Cancer Cachexia: A Systematic Review and Meta-Analysis

    FavorávelMetanáliseDorCâncerEsclerose Múltipla+7
  108. 2019

    N-Palmitoylethanolamide-Oxazoline Protects against Middle Cerebral Artery Occlusion Injury in Diabetic Rats by Regulating the SIRT1 Pathway

  109. 2019

    Role of Cannabinoid Receptor Type 1 in Insulin Resistance and Its Biological Implications

  110. 2019

    The effects of delta-9-tetrahydrocannabinol on Krüppel-like factor-4 expression, redox homeostasis, and inflammation in the kidney of diabetic rat

    FavorávelEstudo em AnimaisInflamaçãoNefropatia Diabética
  111. 2019

    The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus

    FavorávelMetanáliseEndocanabinoide (não especificado)Microbioma
  112. 2018

    A prospective and longitudinal study of plasma phospholipid saturated fatty acid profile in relation to cardiometabolic biomarkers and the risk of gestational diabetes

  113. 2018

    Association of vascular indices with novel circulating biomarkers as prognostic factors for cardiovascular complications in patients with type 2 diabetes mellitus

  114. 2018

    Effects of polymorphism rs3123554 in the cannabinoid receptor gene type 2 (CB2R) on metabolic and adiposity parameters after weight loss with two hypocaloric diets

  115. 2018

    Endocannabinoid system acts as a regulator of immune homeostasis in the gut.

  116. 2018

    LH-21 and abnormal cannabidiol improve β-cell function in isolated human and mouse islets through GPR55-dependent and -independent signalling.

  117. 2018

    Limonene: Aroma of innovation in health and disease

    FavorávelMetanáliseDorCâncerInflamação+2
  118. 2018

    Maternal administration of cannabidiol promotes an anti-inflammatory effect on the intestinal wall in a gastroschisis rat model

    FavorávelEstudo em AnimaisCâncerInflamaçãoEstresse Oxidativo+8
  119. 2018

    METABOLISM| APRIL 12 2018 Cannabinoid Type 1 Receptors Are Upregulated During Acute Activation of Brown Adipose Tissue

  120. 2018

    Peripheral Endocannabinoids Associated With Energy Expenditure in Native Americans of Southwestern Heritage

  121. 2018

    Prevalence of alcohol, tobacco, cannabis and other illicit substance use in a population of Canadian adolescents with type 1 diabetes compared to a general adolescent population

    InconclusivoMetanálise
  122. 2018

    Role of Endocannabinoids on Sweet Taste Perception, Food Preference, and Obesity-related Disorders

  123. 2018

    Spirulina maxima Extract Reduces Obesity through Suppression of Adipogenesis and Activation of Browning in 3T3-L1 Cells and High-Fat Diet-Induced Obese Mice

    FavorávelEstudo em AnimaisObesidadeSíndrome MetabólicaFicocianina
  124. 2018

    Sub-chronic treatment with cannabidiol but not with URB597 induced a mild antidepressant-like effect in diabetic rats

    FavorávelEstudo em AnimaisDepressão
  125. 2018

    The Inhibitory Effects of Cobalt Protoporphyrin IX and Cannabinoid 2 Receptor Agonists in Type 2 Diabetic Mice.

  126. 2018

    The relationship between cannabis use and diabetes: Results from the National Epidemiologic Survey on Alcohol and Related Conditions III

    FavorávelMetanálise
  127. 2018

    Time-dependent effect of phytocannabinoid treatments in fat cells

    FavorávelEstudo LaboratorialObesidadeTetraidrocanabinol (THC)
  128. 2018

    Δ9-Tetrahydrocannabinol Prevents Cardiovascular Dysfunction in STZ-Diabetic Wistar-Kyoto Rats.

  129. 2017

    Ameliorative effect of borneol, a natural bicyclic monoterpene against hyperglycemia, hyperlipidemia and oxidative stress in streptozotocin-induced diabetic Wistar rats

    FavorávelEstudo em AnimaisInflamaçãoDoenças Cardiovasculares (DCV)
  130. 2017

    Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity.

  131. 2017

    Geraniol Alleviates Diabetic Cardiac Complications: Effect on Cardiac Ischemia and Oxidative Stress

  132. 2017

    Medical cannabis: Another piece in the mosaic of autoimmunity?

    FavorávelMetanáliseInflamaçãoEsclerose MúltiplaArtrite+3
  133. 2017

    Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation.

  134. 2017

    Use of palmitoylethanolamide in carpal tunnel syndrome: a prospective randomized study

    InconclusivoEnsaio Clínico Duplo-CegoDorInflamaçãoDor — CrônicaPalmitoiletanolamida (PEA)+5
  135. 2016

    Cannabinoids and autoimmune diseases: A systematic review

  136. 2016

    Chemical characterization of essential oil from seeds of wild and cultivated carrots from Serbia

    FavorávelEstudo LaboratorialDorCâncerInflamação+1
  137. 2016

    Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease

  138. 2016

    Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.

    FavorávelEnsaio Clínico Duplo-CegoEsteatose HepáticaTetraidrocanabivarina (THCV)
  139. 2016

    Endocannabinoid regulation in white and brown adipose tissue following thermogenic activation

  140. 2016

    Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes.

    FavorávelEstudo em Animais
  141. 2016

    Geraniol Improves the Impaired Vascular Reactivity in Diabetes and Metabolic Syndrome Through Calcium Channel Blocking Effect

    FavorávelEstudo em AnimaisSíndrome Metabólica
  142. 2016

    Got Munchies? Estimating the Relationship between Marijuana Use and Body Mass Index.

    FavorávelMetanáliseObesidadeSíndrome MetabólicaPerda de Apetite
  143. 2016

    Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study

  144. 2016

    Lysophosphatidylinositol Signalling and Metabolic Diseases

  145. 2016

    Marijuana Use and Type 2 Diabetes Mellitus: a Review.

    FavorávelMetanálise
  146. 2016

    Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor

  147. 2016

    Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters

  148. 2016

    Relation between postoperative ileus and anastomotic leakage after colorectal resection: a post hoc analysis of a prospective randomized controlled trial

  149. 2015

    Cannabis Smoking and Diabetes Mellitus: Results from Meta-Analysis with Eight Independent Replication Sample.

    FavorávelMetanálise
  150. 2015

    Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH)

    FavorávelMetanáliseSíndrome MetabólicaHIV/AIDSHepatite
  151. 2015

    Cannabis use in relation to obesity and insulin resistance in the Inuit population.

    FavorávelMetanáliseObesidadeSíndrome Metabólica
  152. 2015

    Fetal endocannabinoids orchestrate the organization of pancreatic islet microarchitecture.

    FavorávelEstudo em AnimaisAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+2
  153. 2015

    Palmitoylethanolamide treatment reduces retinal inflammation in streptozotocin-induced diabetic rats

    FavorávelEstudo em AnimaisDorInflamaçãoDor — Neuropatia DiabéticaPalmitoiletanolamida (PEA)+1
  154. 2015

    Phytol in a Pharma-Medico-Stance

  155. 2015

    Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus

  156. 2014

    A role for trans-caryophyllene in the moderation of insulin secretion.

    FavorávelEstudo Laboratorial
  157. 2014

    Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes

    FavorávelEnsaio ClínicoInflamaçãoEstresse OxidativoObesidadeCúrcuma+1
  158. 2014

    Dairy fat intake is associated with glucose tolerance, hepatic and systemic insulin sensitivity, and liver fat but not β-cell function in humans

  159. 2014

    Dietary camphene attenuates hepatic steatosis and insulin resistance in mice

    FavorávelEstudo em AnimaisEsteatose Hepática
  160. 2014

    Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study

    FavorávelMetanáliseSíndrome MetabólicaÁcido Pentadecanoico (C15:0)
  161. 2014

    Glucose metabolism: focus on gut microbiota, the endocannabinoid system and beyond

  162. 2014

    Moderate-vigorous physical activity across body mass index in females: moderating effect of endocannabinoids and temperament

  163. 2014

    Potential first trimester metabolomic biomarkers of abnormal birth weight in healthy pregnancies

  164. 2014

    Protective effects of geraniol (a monoterpene) in a diabetic neuropathy rat model: attenuation of behavioral impairments and biochemical perturbations

    FavorávelEstudo em AnimaisInflamaçãoEstresse OxidativoDoenças Neurodegenerativas+2
  165. 2014

    Serum pentadecanoic acid (15:0), a short-term marker of dairy food intake, is inversely associated with incident type 2 diabetes and its underlying disorders

  166. 2013

    Addition of capsaicin and exchange of carbohydrate with protein counteract energy intake restriction effects on fullness and energy expenditure

  167. 2013

    Antioxidative properties and inhibition of key enzymes relevant to type-2 diabetes and hypertension by essential oils from black pepper

    FavorávelEstudo LaboratorialDoenças Cardiovasculares (DCV)Hipertensão Arterial
  168. 2013

    CB1 Cannabinoid Receptors Couple to Focal Adhesion Kinase to Control Insulin Release.

    FavorávelEstudo em AnimaisAnandamida (AEA)Endocanabinoide (não especificado)+7
  169. 2013

    Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity

  170. 2013

    Metabolic effects of chronic cannabis smoking

  171. 2013

    Preventive and ameliorating effects of citrus D-limonene on dyslipidemia and hyperglycemia in mice with high-fat diet-induced obesity

    FavorávelEstudo em AnimaisObesidadeSíndrome Metabólica
  172. 2013

    Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans

    InconclusivoEnsaio Clínico Duplo-CegoEfeitos Adversos da CannabisAnsiedadeDoenças Cardiovasculares (DCV)+7
  173. 2013

    The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.

    FavorávelEstudo em AnimaisObesidadeCanabinoides Sintéticos AM-xTetraidrocanabivarina (THCV)
  174. 2013

    The impact of marijuana use on glucose, insulin, and insulin resistance among US adults.

    FavorávelMetanáliseObesidadeSíndrome Metabólica
  175. 2012

    A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men

    FavorávelEnsaio Clínico Duplo-CegoSíndrome MetabólicaAnorexia (perda de apetite)HIV/AIDSTetraidrocanabinol (THC)
  176. 2012

    Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria

  177. 2012

    An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain

    FavorávelEnsaio Clínico Duplo-CegoDorAnsiedadeDor — CrônicaTHC Farmacêutico+3
  178. 2012

    Cannabis—A Valuable Drug That Deserves Better Treatment

  179. 2012

    Crosstalk between the gut microbiota and the endocannabinoid system: impact on the gut barrier function and the adipose tissue

  180. 2012

    Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III.

    FavorávelMetanálise
  181. 2012

    Does rimonabant independently affect free fatty acid and glucose metabolism?

  182. 2012

    Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes

  183. 2012

    Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis

  184. 2012

    Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE)

  185. 2012

    The l-α-Lysophosphatidylinositol/GPR55 System and Its Potential Role in Human Obesity

  186. 2011

    Adipose tissue endocannabinoid system gene expression: depot differences and effects of diet and exercise

  187. 2011

    Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress.

  188. 2011

    Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes

  189. 2011

    Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy

  190. 2011

    Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance

    FavorávelEnsaio Clínico Duplo-CegoDorAnsiedadeNáusea e VômitoCanabinoides Sintéticos CP-x+4
  191. 2011

    Minireview: Recent Developments in the Physiology and Pathology of the Lysophosphatidylinositol-Sensitive Receptor GPR55

  192. 2011

    Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients

  193. 2011

    Serum A-FABP is increased and closely associated with elevated NT-proBNP levels in type 2 diabetic patients treated with rosiglitazone

  194. 2011

    Targets of curcumin

    FavorávelMetanáliseCâncerInflamaçãoDoenças Cardiovasculares (DCV)Cúrcuma+16
  195. 2010

    A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes

    DesfavorávelEnsaio Clínico Duplo-CegoObesidade
  196. 2010

    Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, inflammatory and cell death signaling pathways in diabetic cardiomyopathy.

    FavorávelEstudo em AnimaisInflamaçãoDoenças Cardiovasculares (DCV)Estresse Oxidativo
  197. 2010

    Effect of dietary fat on endocannabinoids and related mediators: Consequences on energy homeostasis, inflammation and mood

  198. 2010

    Polymorphisms in the endocannabinoid receptor 1 in relation to fat mass distribution

    DesfavorávelEnsaio ClínicoObesidade
  199. 2009

    Cannabidiol Arrests Onset of Autoimmune Diabetes in NOD Mice.

    FavorávelEstudo em Animais
  200. 2009

    Cannabinoid CB(1) receptor activation stimulates neurite outgrowth and inhibits capsaicin-induced Ca(2+) influx in an in vitro model of diabetic neuropathy.

  201. 2009

    Drug reimbursement and GPs' prescribing decisions: a randomized case-vignette study about the pharmacotherapy of obesity associated with type 2 diabetes: how GPs react to drug reimbursement

    DesfavorávelEnsaio ClínicoObesidade
  202. 2009

    Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial

    InconclusivoEnsaio Clínico Duplo-CegoCanabinoide Sintético (não especificado)
  203. 2009

    Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats

  204. 2009

    Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb

  205. 2008

    SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes

    InconclusivoEnsaio Clínico Duplo-CegoCanabinoide Sintético (não especificado)
  206. 2008

    Targeting the endocannabinoid system: to enhance or reduce?

  207. 2007

    Fatty acid profile of the erythrocyte membrane preceding development of Type 2 diabetes mellitus

    FavorávelEstudo LaboratorialSíndrome MetabólicaÁcido Pentadecanoico (C15:0)
  208. 2007

    High-cholesterol feeding aggravates cerebral infarction via decreasing the CB1 receptor

    FavorávelEstudo em AnimaisObesidadeSíndrome MetabólicaAVC+1
  209. 2007

    Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients

    FavorávelMetanálise ClínicaObesidadeCanabinoide Sintético (não especificado)
  210. 2006

    Cold exposure stimulates synthesis of the bioactive lipid oleoylethanolamide in rat adipose tissue

  211. 2006

    Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus

    FavorávelEnsaio Clínico Duplo-CegoCanabinoide Sintético (não especificado)
  212. 2006

    Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes.

    FavorávelEstudo em AnimaisEstresse OxidativoDoenças NeurodegenerativasDoenças da Retina
  213. 2006

    The cannabinergic system as a target for anti-inflammatory therapies.

  214. 2005

    Cannabidiol lowers incidence of diabetes in non-obese diabetic mice.

    FavorávelEstudo em Animais
  215. 2004

    Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect.

    FavorávelEstudo em AnimaisDorDor — Neuropatia DiabéticaCanabinoides Sintéticos WIN-x
  216. 2004

    Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss

    FavorávelEstudo em AnimaisObesidadeSíndrome MetabólicaDelta-8-THC
  217. 2001

    Examination of the immunosuppressive effect of delta9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes.

    FavorávelEstudo em AnimaisTetraidrocanabinol (THC)
  218. 1893

    Report of the Indian Hemp Drugs Commission, 1893-1894 (Volume 1)

Continue por aqui

Perguntas frequentes

Quantos estudos sobre diabetes estão indexados no acervo?
São 218 estudos, publicados entre 1893 e 2024. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Metanálise: 85 · Estudo em Animais: 59 · Ensaio Clínico: 32 · Ensaio Clínico Duplo-Cego: 19 · Estudo Laboratorial: 18 · Metanálise Clínica: 5. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 175 favoráveis, 18 inconclusivos e 25 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Diabetes — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/condicao/diabetes/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Diabetes — estudos científicos sobre cannabis. https://cannabisindica.com.br/condicao/diabetes/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.